骨化三醇联合奥美沙坦酯治疗早期2型糖尿病肾病的效果及对肾病足细胞损伤的机制探讨

Abstract
Figure/Table
References (25)
Related Citation (2)

Download: PDF (558 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Calcitriol combined with Olmesartan Medoxomil in treatment of early type 2 diabetic nephropathy (T2DN) and the mechanism of nephrotic podocyte damage. Methods A total of 82 early T2DN patients admitted to Wuhu Second People’s Hospital of Anhui Province from January 2018 to December 2019 were selected as the research objects, and they were divided into study group and control group by random number table method, with 41 cases in each group. The control group was treated with Olmesartan Medoxomil on the basis of conventional treatment, and the study group was treated with Calcitriol on the basis of the control group. The clinical efficacy and safety of the two groups were compared, and the levels of microRNA-30 (miR-30) and serum creatinine (Scr) of the two groups were compared before treatment (T0), at week 1 (T1), week 4 (T2) and week 8 (T3) after treatment. Results The curative effect of the study group was better than that of the control group (P ＜ 0.05). The overall analysis found that: the comparison of Scr, miR-30 between groups, time points, and interaction were statistically significant (P ＜ 0.05). Further pairwise comparison, intra-group comparison: at T1, T2, and T3, the levels of Scr and miR-30 in the two groups were lower than those at T0 (P ＜ 0.05). At T2 and T3, the levels of Scr and miR-30 in the two groups were lower than those at T1 (P ＜ 0.05). At T3, the levels of Scr and miR-30 in the two groups were lower than at T2 (P ＜ 0.05). Comparison between groups: At T1, T2, and T3, the levels of Scr and miR-30 in the study group were lower than those in the control group (P ＜ 0.05). During the treatment period, there was no statistically significant difference in the incidence of adverse reactions between the two groups (P ＞ 0.05). Conclusion Calcitriol combined with Olmesartan Medoxomil has a significant effect in the treatment of early T2DN and improves renal podocyte damage. The mechanism may be related to the inhibition of podocyte damage in miR-30 patients.

Key words： Calcitriol Olmesartan Medoxomil Early type 2 diabetic nephropathy Podocyte damage

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Cheng1 SHAO Yunxia1 WU Yan1 XING Changying2▲

Cite this article:

HUANG Cheng1 SHAO Yunxia1 WU Yan1 XING Changying2▲. Effect of Calcitriol combined with Olmesartan Medoxomil in the treatment of early type 2 diabetes nephropathy and its mechanism on nephrotic podocyte damage[J]. 中国医药导报, 2022, 19(15): 79-82.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I15/79

[1] 刘晴，蔡倩，王暴魁.基于足细胞保护探讨中医药治疗糖尿病肾病作用机制的实验研究进展[J].环球中医药，2021，14（1）：169-172.
[2] 连明珠，赵莹，康静，等.达格列净对早期2型糖尿病肾病患者肾小球和肾小管功能的影响[J].中国现代医学杂志，2021，31（2）：13-18.
[3] 尹晓明，李晓飞，赵蓉.云南省2型糖尿病患者糖尿病肾病发病情况及危险因素分析[J].华南预防医学，2021，47（4）：440-444.
[4] 陈洁，罗敏虹，陈兴强，等.miRNA-9-5p与NF-κB信号通路在2型糖尿病肾病发病中的作用机制[J].现代生物医学进展，2019，19（17）：3239-3243，3212.
[5] 马英丽，李文娟.贝那普利与奥美沙坦酯配伍治疗糖尿病肾病33例[J].陕西医学杂志，2016，45（1）：95-96，99.
[6] 何晓玮，钟涛.α硫辛酸辅助奥美沙坦酯对糖尿病肾病患者血清miR-150-5p及miR-155-5p表达的影响[J].中国现代应用药学，2021，38（5）：624-629.
[7] 韦秀芳，阮素莲.尿毒清颗粒联合奥美沙坦治疗早期糖尿病肾病的疗效及对肝肾功能的影响[J].中国老年学杂志，2018，38（4）：874-876.
[8] 黄敏，陈颖，成水芹，等.骨化三醇联合坎地沙坦对早期糖尿病肾病的疗效及对血清Klotho与Vaspin水平的影响[J].中国现代医学杂志，2020，30（7）：53-58.
[9] 牛艳冬，张京慧，温小军，等.替米沙坦联合骨化三醇治疗早期糖尿病肾病患者临床效果及对血清Lp(α)、TGF-β1水平影响[J].临床误诊误治，2021，34（3）：31-35.
[10] 赵晔，于磊，王秀颖，等.维生素D3 治疗糖尿病肾病患者的疗效及肾组织足细胞损伤与ROS,AOPP,SOD的相关性分析[J].疑难病杂志，2020，19（1）：36-40.
[11] 裴剑浩.中国糖尿病诊疗指南解读——糖尿病肾病[J].中国医师杂志，2014（2）：161-163.
[12] 赵进喜，王世东，李靖，等.糖尿病肾脏病分期辨证规范与疗效评定方案及其研究[J].世界中医药，2017，12（1）：1-4.
[13] 李燕妮，仲健，郭秋野，等.糖尿病肾病患者接受普罗布考联合奥美沙坦酯治疗后糖脂代谢、氧化和炎症反应程度的评估[J].海南医学院学报,2016，22（22）：2699-2702.
[14] 管红斌，黄华，桓文穆，等.骨化三醇联合替米沙坦治疗糖尿病肾病的疗效[J].广东医学，2012，33（16）：3.
[15] 张小林.复方黄芪汤联合骨化三醇对糖尿病肾病的效果[J].中国继续医学教育，2021，13（3）：155-158.
[16] 丁红，湛川，王宗谦，等.骨化三醇对糖尿病肾病患者蛋白尿及高敏C反应蛋白的影响[J].山东医药，2011，51（41）：2.
[17] 张秀华，吴立.骨化三醇胶丸联合胰激肽原酶肠溶片对2型糖尿病早期肾病的疗效观察[J].中国药物与临床，2020，20（20）：475-3476.
[18] 杨彩莲，童涛，孙明芳，等.miR-30a和SNAI1基因多态性与糖尿病肾病的相关性分析[J].解放军医学杂志，2021，46（9）：899-905.
[19] 王殿云，卢聪聪，范国霞.桃叶珊瑚苷通过调控miR-30a-5p表达对高糖诱导的肾小管上皮细胞损伤的影响[J].中国免疫学杂志，2021，37（4）：415-420.
[20] 段英连，马婵娟.微小RNA在糖尿病肾病发病机制中的研究进展[J].临床肾脏病杂志，2021，21（3）：243-248.
[21] 赵艳红，李红梅，孙阳.高通量血液透析联合海昆肾喜对糖尿病肾病患者氧化应激及微炎症状态的影响[J].中国医药导报，2020，17（4）：98-101，109.
[22] 李守杰，杨洪洪.骨化三醇治疗糖尿病肾病对患者血糖水平和肾功能的影响[J].系统医学，2021，6（6）：52-54.
[23] 李志琛，陈建斌，梅伟群，等.骨化三醇联合胰激肽原酶治疗早期糖尿病肾病的疗效观察[J].浙江医学，2019， 41（6）：568-570，582.
[24] 乌日娜，王蔚，王小冬，等.社区医院应用骨化三醇联合氯沙坦治疗糖尿病肾病的疗效研究[J].中国临床保健杂志，2019，22（2）：224-228.
[25] 王加英，朱炜炜，万意.骨化三醇联合降糖药物对2型糖尿病肾病患者的疗效分析[J].新疆医科大学学报，2019， 42（12）：1583-1587.